Mankind Pharma IPO:GMP, Price, Dates & size

0
1138
Rate this post

Mankind Pharma Limited has emerged as a leading pharmaceutical company focused on developing, manufacturing, and marketing pharmaceutical formulations and consumer healthcare products. With a strong foothold in India, the company operates in diverse therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory. With an extensive portfolio comprising more than 36 well-known brands such as Manforce (Rx), Moxikind-CV, Amlokind-AT, Unwanted-Kit, Candiforce, Gudcef, Glimestar-M, Prega News, Dydroboon, Codistar, Nurokind-Gold, Nurokind Plus-RF, Nurokind-LC, Asthakind-DX, Cefakind, Monticope, Telmikind-H, Telmikind, Gudcef-CV, and Unwanted-72, Mankind Pharma caters to a wide range of healthcare needs. 

A key driver behind Mankind Pharma’s success in the Indian pharmaceutical market is its extensive distribution network of medical representatives. This robust presence across the country has fostered trust among healthcare professionals, leading to over 80% of doctors in India prescribing Mankind Pharma’s formulations. This recognition is further reinforced by the company’s remarkable domestic sales performance, securing the fourth position in sales during the Financial Year 2022. Mankind Pharma remains dedicated to fulfilling the healthcare requirements of the Indian population and maintains a steadfast commitment to innovation and growth within the pharmaceutical industry. 

 
Mankind Pharma IPO Details 

IPO Date Apr 25, 2023 to Apr 27, 2023 
Listing Date [.] 
Face Value ₹1 per share 
Price ₹1026 to ₹1080 per share 
Lot Size 13 Shares 
Total Issue Size 40,058,844 shares 
(aggregating up to ₹4,326.36 Cr) 
Offer for Sale 40,058,844 shares of ₹1 
(aggregating up to ₹4,326.36 Cr) 
Issue Type Book Built Issue IPO 
Listing At BSE, NSE 
Avalon Technologies IPO:GMP, Price, Dates & size

Mankind Pharma IPO Tentative Timetable 

IPO opens on Apr 25, 2023, and closes on Apr 27, 2023

Event Tentative Date 
Opening Date Apr 25, 2023 
Closing Date Apr 27, 2023 
Basis of Allotment May 3, 2023 
Initiation of Refunds May 4, 2023 
Credit of Shares to Demat May 5, 2023 
Listing Date May 8, 2023 
UPI Mandate Confirmation Cut-Off Time 5.00 PM on the issue closing day 

Company Overview 

Mankind Pharma has established itself as a pharmaceutical company with an extensive distribution network of medical representatives, making it one of the largest in the Indian pharmaceutical market. Their reputation is evident as over 80% of doctors in India trust and prescribe their formulations. In terms of domestic sales, the company achieved a notable ranking of fourth during the Financial Year 2022. The company’s achievements have been recognized through various awards and accolades, including the Best of Bharat Awards 2022 by exchange4media and a Silver Medal from the National Awards for Manufacturing Competitiveness Assessment 2021. 

Mankind Pharma

With a wide-ranging marketing presence across India, Mankind Pharma employs a dedicated team of 11,691 medical representatives and 3,561 field managers as of December 31, 2022. To support its operations, the company operates 25 manufacturing facilities throughout the country and employs 4,121 manufacturing personnel. Additionally, Mankind Pharma places great emphasis on research and development, boasting a team of over 600 scientists and a dedicated in-house R&D center with four units located in IMT Manesar, Gurugram, Haryana, and Thane, Maharashtra. 

Industry Overview 

The industry is characterized by rigorous regulatory frameworks, extensive research and development efforts, and a constant drive for innovation. Pharmaceutical companies like Mankind Pharma contribute to the development of new drugs, formulations, and treatment options, addressing a wide range of diseases and medical needs. 

In terms of industry growth, the pharmaceutical sector has historically exhibited a positive Compound Annual Growth Rate (CAGR).  While specific CAGR figures may vary depending on the timeframe and market conditions, the global pharmaceutical industry has typically shown steady growth due to factors such as an aging population, rising healthcare spending, increasing prevalence of chronic diseases, and advancements in medical technologies. 

Company Financials  

Period Ended Total Assets Total Revenue Profit After Tax Net Worth Reserves and Surplus Total Borrowing 
31-Mar-20 5,073.29 5,975.65 1,056.15 3,485.31 3,436.34 126.92 
31-Mar-21 6,372.63 6,385.38 1,293.03 4,722.00 4,674.39 234.53 
31-Dec-21 8,043.88 6,218.29 1,260.24 5,965.46 5,916.86 268.70 
31-Mar-22 9,147.74 7,977.58 1,452.96 6,155.23 6,106.06 868.03 
31-Dec-22 9,273.75 6,777.82 1,015.98 7,145.89 7,094.12 167.93 
Amount in ₹ Crore 

Key Performance Indicator 

KPI Values 
P/E (x) 32.5 
Market Cap (₹ Cr.) 43263.6 
ROE (%) 27.6 
ROCE (%) 26.1 
EPS (Rs) 33.2 
RoNW (%) 27.7 

Objects of the Issue 

The company will not receive any proceeds from the offer and all the offer proceeds will be received by the selling shareholders, in proportion to the offered shares sold by the respective selling shareholders as part of the offer. 

Strengths 

Extensive Distribution Network 

Strong Brand Portfolio 

High Doctor Prescriptions 

Weaknesses 

Regulatory Compliance 

Competitive Landscape 

Dependency on Doctors’ Prescriptions 

Mankind Pharma IPO Prospectus

Company Contact Information

Mankind Pharma Limited
208, Okhla Industrial Estate
Phase-III,
New Delhi 110020
Phone: +91 11 4684 6700
Email: investors@mankindpharma.com
Websitehttps://www.mankindpharma.com/

Mankind Pharma IPO Registrar

Kfin Technologies Limited

Phone: 04067162222, 04079611000
Email: mankind.ipo@kfintech.com
Websitehttps://karisma.kfintech.com/

Mankind Pharma IPO Lead Manager(s)

  1. Kotak Mahindra Capital Company Limited (Past IPO Performance)
  2. Axis Capital Limited (Past IPO Performance)
  3. Iifl Securities Ltd (Past IPO Performance)
  4. Jefferies India Private Limited (Past IPO Performance)
  5. J.P. Morgan India Private Limited (Past IPO Performance)

LEAVE A REPLY

Please enter your comment!
Please enter your name here